VEGFA and gastric cancer: Accordingly, the monoclonal antibodies bevaczizumab and ramucirumab targeting VEGF and VEGF signaling improved outcomes for patients with NSCLC, CRC and gastric cancer (Hurwitz et al., 2004; Sandler et al., 2006; Miller et al., 2007; Ohtsu et al., 2011; Garon et al., 2014; Tabernero et al., 2015).